This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
by Ahan Chakraborty
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
AZNPositive Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
by Ahan Chakraborty
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
AZNPositive Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
by Ahan Chakraborty
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
AZNPositive Net Change JNJNegative Net Change BDTXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
by Kinjel Shah
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
AZNPositive Net Change BMYPositive Net Change JNJNegative Net Change PFEPositive Net Change
pharmaceuticals
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer
by Zacks Equity Research
Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer are benefiting from innovation, pipeline growth and strong demand in key therapies.
JNJNegative Net Change NVOPositive Net Change LLYNegative Net Change BAYRYNegative Net Change
pharmaceuticals
Can Asceniv Help ADMA Navigate the Current IG Market Challenges?
by Ekta Bagri
ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.
GRFSNegative Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
by Zacks Equity Research
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
BMYPositive Net Change MRKNegative Net Change AGENPositive Net Change
biotechs medical pharmaceuticals
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
by Ahan Chakraborty
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Stocks With Solid Net Profit Margins to Strengthen Your Portfolio
by Anirudha Bhagat
Here we present four stocks, ATLC, BTSG, ASX and ENVA, with solid net profit margins that can contribute to making a strong portfolio.
ASXNegative Net Change ENVAPositive Net Change ATLCPositive Net Change BTSGPositive Net Change
computers fin-tech medical medical-devices pharmaceuticals semiconductor tech-stocks